Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
View/ Open
Date
2012-06Author
Mureithi Marianne W.
Poole, Danielle
Naranbhai, Vivek
Reddy, Shabashini
Mkhwanazi, Nompumelelo P.
Sibeko, Sengeziwe
Werner, Lise
Karim, Quarraisha Abdool
Karim, Salim Abdool
Ndung’u, Thumbi
Altfeld, Marcus
The CAPRISA004 Trial Group
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
The Centre for the AIDS Program of Research in South
Africa 004 trial demonstrated reduction of sexual HIV-1 acquisition
in women using a vaginal microbicide containing tenofovir. A better
understanding of the consequences of antiretroviral-containing
microbicides for immune responses in individuals with intercurrent
HIV-1 infection is needed for future trials combining the use of
microbicides with HIV-1 vaccines. Investigation of immune
responses in women who acquired HIV-1 although using tenofovir
gel showed significantly higher (P = 0.01) Gag-specific IFNg+
CD4+ T-cell responses. The use of tenofovir-containing gel around
the time of infection can modulate HIV-1 immunity, and these
immunological changes need to be considered in future trials combining
vaccines and microbicides.
URI
http://www.ncbi.nlm.nih.gov/pubmed/22362152http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/16596
Citation
J Acquir Immune Defic Syndr.Publisher
Department of Medicine. College of Health Sciences. University of Nairobi
Collections
- Faculty of Health Sciences (FHS) [10387]